Quest Diagnostics Incorporated (NYSE:DGX) Stock Position Decreased by LSV Asset Management

LSV Asset Management lessened its stake in Quest Diagnostics Incorporated (NYSE:DGX - Free Report) by 61.8% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 374,770 shares of the medical research company's stock after selling 605,652 shares during the period. LSV Asset Management owned about 0.33% of Quest Diagnostics worth $51,673,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in DGX. JPMorgan Chase & Co. grew its position in Quest Diagnostics by 36.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,001,347 shares of the medical research company's stock valued at $243,884,000 after acquiring an additional 538,377 shares in the last quarter. American Century Companies Inc. grew its holdings in shares of Quest Diagnostics by 12.3% in the third quarter. American Century Companies Inc. now owns 3,554,517 shares of the medical research company's stock valued at $433,153,000 after purchasing an additional 388,162 shares in the last quarter. Wellington Management Group LLP increased its stake in Quest Diagnostics by 14.6% during the 3rd quarter. Wellington Management Group LLP now owns 2,613,793 shares of the medical research company's stock worth $318,517,000 after buying an additional 333,947 shares during the period. Pathstone Family Office LLC lifted its holdings in Quest Diagnostics by 2,400.9% during the 3rd quarter. Pathstone Family Office LLC now owns 336,521 shares of the medical research company's stock worth $41,008,000 after buying an additional 323,065 shares in the last quarter. Finally, AEGON ASSET MANAGEMENT UK Plc purchased a new position in Quest Diagnostics in the 4th quarter valued at approximately $30,869,000. Hedge funds and other institutional investors own 88.06% of the company's stock.

Insiders Place Their Bets

In other news, SVP Karthik Kuppusamy sold 1,760 shares of the stock in a transaction that occurred on Monday, April 29th. The stock was sold at an average price of $140.00, for a total value of $246,400.00. Following the completion of the sale, the senior vice president now directly owns 13,435 shares of the company's stock, valued at $1,880,900. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Quest Diagnostics news, SVP Michael E. Prevoznik sold 5,611 shares of the stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $125.88, for a total transaction of $706,312.68. Following the completion of the sale, the senior vice president now directly owns 38,478 shares of the company's stock, valued at approximately $4,843,610.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Karthik Kuppusamy sold 1,760 shares of the business's stock in a transaction that occurred on Monday, April 29th. The shares were sold at an average price of $140.00, for a total value of $246,400.00. Following the completion of the transaction, the senior vice president now directly owns 13,435 shares in the company, valued at approximately $1,880,900. The disclosure for this sale can be found here. Insiders have sold a total of 16,910 shares of company stock valued at $2,159,602 over the last quarter. Company insiders own 0.79% of the company's stock.

Quest Diagnostics Stock Up 0.8 %

Shares of NYSE DGX traded up $1.04 during mid-day trading on Friday, reaching $137.38. The company had a trading volume of 640,502 shares, compared to its average volume of 1,062,704. The firm has a 50 day simple moving average of $130.33 and a two-hundred day simple moving average of $131.83. Quest Diagnostics Incorporated has a 52-week low of $119.59 and a 52-week high of $145.58. The company has a current ratio of 0.97, a quick ratio of 0.89 and a debt-to-equity ratio of 0.59. The stock has a market cap of $15.26 billion, a P/E ratio of 18.49, a PEG ratio of 2.98 and a beta of 0.88.

Quest Diagnostics (NYSE:DGX - Get Free Report) last issued its quarterly earnings data on Tuesday, April 23rd. The medical research company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.86 by $0.18. Quest Diagnostics had a return on equity of 15.52% and a net margin of 9.11%. The company had revenue of $2.37 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same quarter last year, the company posted $2.04 earnings per share. The business's quarterly revenue was up 1.7% compared to the same quarter last year. Sell-side analysts predict that Quest Diagnostics Incorporated will post 8.78 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on DGX shares. StockNews.com lowered Quest Diagnostics from a "buy" rating to a "hold" rating in a research report on Friday. Mizuho increased their price target on Quest Diagnostics from $150.00 to $155.00 and gave the company a "buy" rating in a research report on Wednesday, April 24th. UBS Group lifted their price objective on Quest Diagnostics from $139.00 to $146.00 and gave the company a "neutral" rating in a research note on Wednesday, April 24th. Truist Financial upped their target price on shares of Quest Diagnostics from $145.00 to $150.00 and gave the stock a "hold" rating in a research note on Wednesday, April 24th. Finally, Leerink Partnrs reiterated a "market perform" rating on shares of Quest Diagnostics in a research note on Monday, February 26th. Ten research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $146.17.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.